Last reviewed · How we verify

Arformoterol Tartrate Inhalation Solution — Competitive Intelligence Brief

Arformoterol Tartrate Inhalation Solution (Arformoterol Tartrate Inhalation Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta-2 adrenergic agonist (LABA). Area: Respiratory / Pulmonology.

marketed Long-acting beta-2 adrenergic agonist (LABA) Beta-2 adrenergic receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Arformoterol Tartrate Inhalation Solution (Arformoterol Tartrate Inhalation Solution) — Sumitomo Pharma America, Inc.. Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Arformoterol Tartrate Inhalation Solution TARGET Arformoterol Tartrate Inhalation Solution Sumitomo Pharma America, Inc. marketed Long-acting beta-2 adrenergic agonist (LABA) Beta-2 adrenergic receptor
Akovaz EPHEDRINE marketed Norepinephrine Releasing Agent Beta-2 adrenergic receptor 2016-01-01
Striverdi Respimat OLODATEROL Boehringer Ingelheim marketed beta2-Adrenergic Agonist Beta-2 adrenergic receptor 2014-01-01
Breo Ellipta VILANTEROL Glaxo Grp Ltd marketed beta2-Adrenergic Agonist Beta-2 adrenergic receptor 2013-01-01
Arcapta Neohaler INDACATEROL Novartis marketed beta2-Adrenergic Agonist Beta-2 adrenergic receptor 2011-01-01
Brovana ARFORMOTEROL Lupin marketed beta2-Adrenergic Agonist Beta-2 adrenergic receptor 2006-01-01
Foradil FORMOTEROL Novartis marketed beta2-Adrenergic Agonist Beta-2 adrenergic receptor 2001-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Long-acting beta-2 adrenergic agonist (LABA) class)

  1. Henry Ford Health System · 1 drug in this class
  2. Sumitomo Pharma America, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Arformoterol Tartrate Inhalation Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/arformoterol-tartrate-inhalation-solution. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: